Stock listing

NASDAQ:SYRE Spyre Therapeutics, Inc. Stock

Home listing (NASDAQ) of Spyre Therapeutics, Inc.

Follow Spyre Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SYRE

$93.47 USD -7.99 (-7.9%)

Close on Nov 20, 2026

Past year +298.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$93.22 – $99.56 USDNov 20, 2026
Volume
805,350 sharesNov 20, 2026
Market cap
$8.88B USDAt the close on Nov 20, 2026 · price × 94.97M shares outstanding
52-week range
$23.01 – $110.64 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$114.8M USDMedian day 1.10M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Spyre Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SYRE · Home$93.47 USD-7.99 (-7.9%)805,350$95.93$99.56$93.22$101.46Close on Nov 20, 2026
Frankfurt:3920€87.00 EUR-5.50 (-5.9%)—€87.00€87.00€87.00€92.50Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SYRE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$93.47-7.99-7.9%$95.93$99.56$93.22805,350
$101.46+7.65+8.2%$93.61$102.72$93.511,371,847
$93.81-5.56-5.6%$98.70$100.04$92.981,102,434
$99.37-4.63-4.5%$102.26$106.20$98.81824,685
$104.00+1.09+1.1%$102.33$104.50$100.49746,230
$102.91-3.91-3.7%$105.21$105.28$101.40985,828
$106.82+2.34+2.2%$104.71$107.87$103.72894,432
$104.48-4.52-4.1%$106.95$109.15$103.191,003,963
$109.00+5.14+4.9%$105.59$110.64$104.411,393,580
$103.86+7.27+7.5%$98.35$104.25$97.291,630,339
$96.59-2.45-2.5%$98.38$98.75$93.831,160,382
$99.04-0.23-0.2%$99.00$100.00$92.771,470,188
$99.27+3.76+3.9%$97.04$100.00$96.51902,838
$95.51-1.05-1.1%$97.11$98.00$93.83749,263
$96.56-2.40-2.4%$96.78$98.96$94.68658,464
$98.96-0.79-0.8%$99.71$100.42$97.96567,627
$99.75+0.705+0.7%$98.39$100.06$97.55724,412
$99.05+6.135+6.6%$93.00$99.24$92.95944,289
$92.91+2.58+2.9%$91.54$94.19$90.42637,157
$90.33-2.00-2.2%$90.71$91.90$88.69503,000
$92.33-0.62-0.7%$92.95$94.57$91.27802,900
$92.95+1.55+1.7%$92.78$95.17$92.321,153,100
$91.40+6.68+7.9%$85.12$93.22$85.081,708,500
$84.72+4.82+6.0%$82.29$86.05$80.941,272,000
$79.90-0.20-0.2%$80.21$80.52$78.131,273,300
$80.10+1.47+1.9%$76.87$80.88$76.871,148,000
$78.63-1.82-2.3%$80.13$82.45$77.951,624,600
$80.45-5.45-6.3%$85.12$85.32$80.451,441,000
$85.90+0.21+0.2%$86.30$86.62$84.21873,900
$85.69+5.79+7.2%$79.90$86.22$78.731,116,400
$79.90-0.95-1.2%$79.58$80.91$77.052,326,700
$80.85+0.74+0.9%$78.91$82.22$78.002,719,300
$80.11-12.61-13.6%$92.08$92.08$79.364,252,300
$92.72-0.47-0.5%$93.02$95.01$89.49642,800
$93.19+3.26+3.6%$91.16$95.27$90.481,235,000
$89.93+0.90+1.0%$89.13$94.06$87.251,662,600
$89.03+4.31+5.1%$88.64$95.08$88.002,096,000
$84.72-1.07-1.2%$85.09$86.64$83.261,053,200
$85.79+0.10+0.1%$84.72$87.12$84.001,045,400
$85.69-1.40-1.6%$88.10$88.10$85.63560,100
$87.09-1.08-1.2%$87.46$87.46$82.931,729,600
$88.17-3.80-4.1%$91.56$91.56$86.30918,800
$91.97-0.06-0.1%$91.53$93.58$89.901,223,400
$92.03+1.78+2.0%$91.07$94.06$89.651,448,700
$90.25-2.43-2.6%$92.82$93.34$89.853,357,100
$92.68+1.51+1.7%$92.86$95.19$91.141,438,900
$91.17+0.22+0.2%$91.38$93.07$90.481,257,600
$90.95+0.15+0.2%$90.82$91.07$88.47858,500
$90.80+0.20+0.2%$90.21$91.40$89.431,101,200
$90.60+1.89+2.1%$90.00$91.41$87.89886,100
$88.71+1.78+2.0%$85.56$88.72$85.26902,400
$86.93-3.86-4.3%$88.07$89.57$86.851,005,800
$90.79+1.81+2.0%$85.00$92.10$85.001,248,800
$88.98+1.73+2.0%$86.45$89.18$84.68803,800
$87.25+0.20+0.2%$86.71$87.90$85.781,054,200
$87.05-1.45-1.6%$88.05$90.18$84.001,361,500
$88.50-0.83-0.9%$87.06$90.00$85.001,429,000
$89.33-1.03-1.1%$89.15$90.97$86.401,913,200
$90.36-3.255-3.5%$91.75$93.39$89.451,266,500
$93.62+0.010.0%$93.61$94.95$91.251,165,300
$93.61-13.75-12.8%$92.41$96.22$90.603,114,200
$107.36+0.71+0.7%$109.02$110.15$106.94923,600
$106.65+0.16+0.2%$106.49$108.02$104.94640,600
$106.49-1.30-1.2%$108.85$110.00$105.711,014,900
$107.79-1.13-1.0%$106.60$108.18$104.56700,600

Splits

1 split · NASDAQ:SYRE · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
Ticker
NASDAQ:SYRE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Spyre Therapeutics, Inc. news

Spyre Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 148 in all · newest Nov 10, 2026 · oldest 2019
Decks
32 decks · latest October 2026

Where Spyre Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SYRE · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A3D4LYLS ExchangeGermanyEUR
BOATS:SYREBOATSUnited StatesUSD
Lang & Schwarz:A3D4LYLang & SchwarzGermanyEUR
Dusseldorf:3920DusseldorfGermanyEUR
Tradegate:3920TradegateGermanyEUR
Stuttgart:3920StuttgartGermanyEUR
Frankfurt:3920FrankfurtGermanyEUR
gettex:3920gettexGermanyEUR
Munich:3920MunichGermanyEUR
Xetra:3920XetraGermanyEUR

Valuation

EV/sales 86.3× against a median of 17.5×: 7th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$7.80B USD
P/E
Loss
EV/sales
86.3×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
8.4×
Gross margin
Not reported
Operating margin
−276.4%
Net margin
−291.6%
Debt to equity
0.0×
Beta vs S&P 500
1.71

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Spyre Therapeutics, Inc. · NASDAQ:SYREUS$8.88BUS$7.80Bn/a86.3×n/a8.4×−291.6%0.0×1.71
Halozyme Therapeutics, Inc. · NASDAQ:HALOUS$10.41BUS$12.59B21.5×7.0×18.2×n/a26.9%n/a0.63
Kymera Therapeutics, Inc. · NASDAQ:KYMRUS$9.84BUS$8.87Bn/a86.8×n/a6.1×−341.8%0.0×0.92
TG Therapeutics, Inc. · NASDAQ:TGTXUS$9.70BUS$9.94B91.4×11.1×51.5×16.9×11.8%1.3×0.70
Krystal Biotech, Inc. · NASDAQ:KRYSUS$9.15BUS$8.24B40.6×17.5×35.3×6.4×47.9%0.0×0.69
Alteogen Inc. · KRX:196170US$9.06BUS$8.73B63.2×46.0×91.9×22.6×75.5%0.0×n/a
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H · HKEX:6990US$8.99BUS$8.28B473×25.1×338×11.2×5.8%0.0×n/a
Vaxcyte, Inc. · NASDAQ:PCVXUS$8.77BUS$7.70Bn/an/an/a3.5×n/a0.1×1.24
Praxis Precision Medicines, Inc. · NASDAQ:PRAXUS$8.40BUS$7.65Bn/an/an/a6.7×n/a0.0×1.45
Summit Therapeutics Inc. · NASDAQ:SMMTUS$7.96BUS$7.33Bn/an/an/a14.1×n/a0.0×1.91
Protagonist Therapeutics, Inc. · NASDAQ:PTGXUS$7.92BUS$7.13B23.1×12.9×22.0×7.3×62.0%0.0×0.93
Median of the othersUS$9.02BUS$8.26B52.0×17.5×43.4×7.3×26.9%0.0×0.93

Forecasts

16 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
123.87 USD · Analysts' mean
EPS, year to Dec 2026
-3.04 · 13 analysts

Team and board

Officers

OfficerRole
Cameron TurtleChief Executive Officer
Heidy King-JonesChief Legal Officer and Corporate Secretary
Eric McIntyreSVP of Finance and Investor Relations

Board

DirectorRole
Jeff AlbersChair of the Compensation Committee
Laurie StelzerChair of the Audit Committee
Mark McKennaBoard Member
Michael HendersonBoard Member
Sandra MilliganChair of the Nominating and Corporate Governance Committee
Tomas KiselakMember of the Compensation Committee

Events

QuarterResultsShare move
Q3 2026Nov 3, 2026 · After close−0.2%
Q2 2026Aug 4, 2026 · After close−0.6%
Q1 2026May 7, 2026+2.8%
Q4 2025Feb 19, 2026 · After close+14.3%
Q3 2025Nov 4, 2025 · After close−0.6%
Q2 2025Aug 5, 2025 · After close−5.4%
Q1 2025May 8, 2025 · After close+9.6%
Q4 2024Feb 26, 2025 · After close−3.3%
Q3 2024Nov 7, 2024 · After close+5.0%
Q2 2024Aug 7, 2024 · After close+2.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close+4.9%
Q4 2023Feb 29, 2024 · After close+9.0%
Q3 2023Nov 9, 2023 · After close+0.2%
Q2 2023Aug 11, 2023 · Before open−4.8%
Q1 2023May 11, 2023 · Before open−3.7%
Q4 2022Mar 2, 2023−0.3%
Q3 2022Nov 3, 2022 · Before open−6.6%
Q2 2022Aug 4, 2022 · Before open+6.4%
Q1 2022May 5, 2022−10.9%
Q4 2021Mar 8, 2022 · Before open+3.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck36 slidesOctober 2026
Technical Presentation (April 2026)Technical31 slidesApr 13, 2026
Investor Presentation (January 2026)Investor deck38 slidesJan 12, 2026
Technical Presentation (June 2025)Technical36 slidesJun 17, 2025
Investor Presentation (January 2025)Investor deck58 slidesJan 13, 2025
Corporate Update (November 2024)Corporate update31 slidesNov 12, 2024
Investor Presentation (October 2024)Investor deck49 slidesOct 15, 2024
Aeglea BioTherapeutics — Investor Presentation (October 2023)Investor deck38 slidesOct 24, 2023
Aeglea BioTherapeutics — Investor Presentation (September 2023)Investor deck56 slidesSep 8, 2023
Aeglea BioTherapeutics — Merger or Acquisition (June 2023)Merger or acquisition50 slidesJun 23, 2023
All 32 decks
DeckKindSlidesDate
Aeglea BioTherapeutics — Investor Presentation (April 2023)Investor deck37 slidesApr 25, 2023
Aeglea BioTherapeutics — Investor Presentation (March 2023)Investor deck39 slidesMar 2, 2023
Aeglea BioTherapeutics — Investor Presentation (January 2023)Investor deck38 slidesJan 9, 2023
Aeglea BioTherapeutics — Investor Presentation (November 2022)Investor deck43 slidesNov 3, 2022
Aeglea BioTherapeutics — Investor Presentation (September 2022)Investor deck43 slidesSep 6, 2022
Aeglea BioTherapeutics — Investor Presentation (August 2022)Investor deck41 slidesAug 4, 2022
Aeglea BioTherapeutics — Investor Presentation (May 2022)Investor deck42 slidesMay 5, 2022
Aeglea BioTherapeutics — Investor Presentation (April 2022)Investor deck42 slidesApr 12, 2022
Aeglea BioTherapeutics — Investor Presentation (March 2022)Investor deck40 slidesMar 8, 2022
Aeglea BioTherapeutics — Investor Presentation (January 2022)Investor deck40 slidesJan 5, 2022
Aeglea BioTherapeutics — Technical Presentation (December 2021)Technical23 slidesDec 6, 2021
Aeglea BioTherapeutics — Investor Presentation (September 2021)Investor deck39 slidesSep 9, 2021
Aeglea BioTherapeutics — Investor Presentation (March 2021)Investor deck46 slidesMar 18, 2021
Aeglea BioTherapeutics — Investor Presentation (January 2021)Investor deck39 slidesJan 5, 2021
Aeglea BioTherapeutics — Technical Presentation (May 2020)Technical13 slidesMay 26, 2020
Aeglea BioTherapeutics — Investor Presentation (April 2020)Investor deck40 slidesApr 27, 2020
Aeglea BioTherapeutics — Investor Presentation (January 2020)Investor deck35 slidesJan 13, 2020
Aeglea BioTherapeutics — Investor Presentation (December 2019)Investor deck32 slidesDec 3, 2019
Aeglea BioTherapeutics — Investor Presentation (September 2019)Investor deck36 slidesSep 3, 2019
Aeglea BioTherapeutics — Investor Presentation (April 2019)Investor deck34 slidesApr 8, 2019
Aeglea BioTherapeutics — Technical Presentation (April 2019)Technical14 slidesApr 8, 2019
Aeglea BioTherapeutics — Investor Presentation (December 2018)Investor deck13 slidesDec 11, 2018

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$400M raised · US$85 a share · Jefferies +4
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Leerink Partners (co-lead), Stifel (co-lead), LifeSci Capital
Use of proceeds: To fund a pivotal program in hidradenitis suppurativa with SPY072, its TL1A monotherapy
Nov 3, 2026
At-the-market programme of common stock
Tranche closed: US$18M raised
Nov 3, 2026
Public offering of common stock
Made bigger: about US$403M · US$62 a share · Jefferies LLC +4
Dealers: Jefferies LLC (co-lead), Goldman Sachs & Co. LLC (co-lead), Evercore ISI (co-lead), Guggenheim Securities, LLC (co-lead), LifeSci Capital LLC
Apr 14, 2026
Public offering of common stock
Closed: US$316.2M raised · US$18.5 a share · Jefferies LLC +4
Dealers: Jefferies LLC (co-lead), TD Securities (USA) LLC (co-lead), Leerink Partners LLC (co-lead), Stifel, Nicolaus & Company, Incorporated (co-lead), Wedbush Securities Inc.
Oct 15, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Aeglea BioTherapeutics, Inc. Priced at US$10.00 a share on Apr 6, 2016.

Price
US$10.00 a share
Shares offered
5,000,000 shares of common stock
Offering size
US$50 million
Underwriters' option
Up to 750,000 more shares
Underwriters
UBS Investment Bank, BMO Capital Markets, Wells Fargo Securities, Needham & Company · In the order on the cover
Shares delivered
On or about Apr 12, 2016

Steps

StepWhen
Draft sent to the SEC in confidenceMay 6, 2015
Filed publiclyJun 16, 2015
Amended 6 timesNewest Apr 7, 2016
Shares registered with an exchangeMar 28, 2016
Declared effective by the SECApr 7, 2016
Final prospectus, with the priceApr 7, 2016

Open IPO · From the cover of the final prospectus (424B4) filed Apr 7, 2016

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00886.0K2.33M18.7M003.89M5.21M4.63M
Cost of revenue171.7M964.0K964.0K1.96M2.00M1.62M901.0K
Gross profit-171.7M886.0K-78.0K2.33M18.7M-1.62M-901.0K3.89M5.21M4.63M
Research and development171.7M162.8M89.5M58.6M57.1M59.6M64.6M36.7M22.8M18.1M
Selling, general and administrative47.9M45.8M39.9M28.5M27.3M21.8M17.8M
Operating income-209.6M-208.6M-242.3M-84.8M-65.6M-81.5M-80.3M-45.5M-27.7M-21.9M
Depreciation and amortization00744.0K1.57M1.58M996.0K418.0K293.0K249.0K132.0K
EBITDA-209.6M-208.6M-241.6M-83.2M-64.1M-80.5M-79.9M-45.2M-27.4M-21.8M
Income before tax-155.2M-208.0M-338.8M-84.0M-65.7M-80.9M-78.3M-44.3M-27.2M-21.7M
Income tax-15.0K51.0K-26.0K-136.0K141.0K00000
Net income-155.2M-208.0M-338.8M-83.8M-65.8M-80.9M-78.3M-44.3M-27.2M-21.7M
Earnings per share, basic-1.98-3.4513.76-24.86-25.02-1.52-2.45-2.13-1.80-2.22
Earnings per share, diluted13.76-24.86-25.02-1.52-2.45-2.13-1.80-2.22

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents85.7M89.4M188.9M34.9M15.1M90.1M19.3M22.5M12.8M47.7M
Short-term investments670.8M513.7M150.4M20.8M78.0M56.2M52.7M52.1M37.5M15.8M
Receivables375.0K815.0K300.0K3.08M1.22M
Current assets777.8M608.5M341.5M62.3M98.9M149.8M74.5M76.7M55.0M66.4M
Property, plant and equipment03.22M4.55M5.64M2.38M1.02M854.0K599.0K
Total assets777.8M608.5M341.9M71.1M109.9M161.6M83.2M77.7M56.1M67.1M
Accounts payable8.90M666.0K896.0K677.0K3.32M2.25M3.15M663.0K389.0K168.0K
Current liabilities58.7M54.1M32.0M14.7M20.1M16.4M18.4M10.2M5.63M3.96M
Total debt84.6M84.6M4.63M5.06M5.45M5.12M
Total liabilities62.5M90.7M73.3M20.8M26.0M21.8M23.1M10.3M5.74M4.10M
Shareholders' equity715.2M517.8M184.0M50.3M83.9M139.8M60.1M67.4M50.3M63.0M
Shares outstanding78.2M60.3M36.1M2.61M49.4M48.0M29.1M24.1M16.7M13.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-169.3M-157.4M-99.9M-80.1M-53.7M-75.8M-65.7M-32.2M-24.6M-18.8M
Capital spending000-38.0K-573.0K-4.28M-1.49M-422.0K-619.0K-212.0K
Free cash flow-169.3M-157.4M-99.9M-80.2M-54.3M-80.1M-67.2M-32.6M-25.2M-19.1M
Cash from investing-143.5M-353.3M-108.4M57.0M-22.6M-7.60M-1.74M-15.2M-22.5M-12.1M
Cash from financing309.0M410.9M361.1M42.7M1.39M154.5M65.7M57.1M12.2M49.4M
Change in cash-3.70M-99.8M152.8M19.4M-75.0M71.2M-1.71M9.64M-34.9M18.5M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 3, 2026ResultsSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 9, 2026Big-stake noticeSEC
8-K · Current reportOct 7, 2026Material contractSEC
424B5 · ProspectusOct 6, 2026Offer documentSEC
424B5 · ProspectusOct 5, 2026Offer documentSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeOct 1, 2026Big-stake noticeSEC
144 · Notice of proposed saleSep 30, 2026Other filingsSEC
8-K · Current reportSep 8, 2026Current reportSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
8-K · Current reportAug 25, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
8-K · Current reportAug 4, 2026ResultsSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
S-3ASR · Registration statementJun 26, 2026Offer documentSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 23, 2026Big-stake noticeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
8-K · Current reportJun 15, 2026Current reportSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
144 · Notice of proposed saleJun 3, 2026Other filingsSEC
8-K · Current reportJun 1, 2026Current reportSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
8-K · Current reportMay 29, 2026Management or board changeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
144 · Notice of proposed saleMay 8, 2026Other filingsSEC
8-K · Current reportMay 5, 2026ResultsSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeApr 22, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 20, 2026Big-stake noticeSEC
8-K · Current reportApr 16, 2026Material contractSEC
424B5 · ProspectusApr 15, 2026Offer documentSEC
424B5 · ProspectusApr 13, 2026Offer documentSEC
8-K · Current reportApr 13, 2026ResultsSEC
8-K · Current reportApr 13, 2026Current reportSEC
ARS · Annual report to shareholdersApr 10, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 10, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 10, 2026Meeting noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMar 5, 2026Other filingsSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 2, 2026Other filingsSEC
POS AM · Amendment to an effective registrationFeb 27, 2026Offer documentSEC
CORRESP · Letter to the SECFeb 25, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 25, 2026Other filingsSEC
S-3 · Registration statementFeb 19, 2026Offer documentSEC
S-8 · Registration statement for employee plansFeb 19, 2026Offer documentSEC
8-K · Current reportFeb 19, 2026ResultsSEC
10-K · Annual reportFeb 19, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
8-K · Current reportNov 4, 2025ResultsSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
144 · Notice of proposed saleNov 3, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
8-K · Current reportOct 15, 2025Material contractSEC
424B5 · ProspectusOct 14, 2025Offer documentSEC
424B5 · ProspectusOct 14, 2025Offer documentSEC
8-K · Current reportOct 14, 2025ResultsSEC
4 · Change in ownershipSep 3, 2025Insider tradeSEC
S-8 · Registration statement for employee plansAug 5, 2025Offer documentSEC
8-K · Current reportAug 5, 2025ResultsSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
8-K · Current reportJun 17, 2025Current reportSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
8-K · Current reportJun 2, 2025Meeting outcomeSEC
UPLOAD · Letter from the SECJun 2, 2025Other filingsSEC
CORRESP · Letter to the SECMay 21, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 9, 2025Other filingsSEC
8-K · Current reportMay 8, 2025ResultsSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeMay 1, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 14, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 14, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 14, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveMar 14, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 10, 2025Other filingsSEC
POS AM · Amendment to an effective registrationMar 7, 2025Offer documentSEC
8-K · Current reportMar 6, 2025Current reportSEC
CORRESP · Letter to the SECMar 5, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 4, 2025Other filingsSEC
S-3 · Registration statementFeb 27, 2025Offer documentSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
8-K · Current reportFeb 27, 2025ResultsSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025ResultsSEC
8-K · Current reportNov 19, 2024Material contractSEC
424B5 · ProspectusNov 19, 2024Offer documentSEC
424B5 · ProspectusNov 18, 2024Offer documentSEC
10-Q/A · Quarterly report, amendedNov 18, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedNov 18, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedNov 18, 2024Quarterly reportSEC
10-K/A · Annual report, amendedNov 18, 2024Annual reportSEC
8-K · Current reportNov 18, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
8-K · Current reportNov 12, 2024Current reportSEC
4 · Change in ownershipNov 8, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 7, 2024Offer documentSEC
8-K · Current reportNov 7, 2024ResultsSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
4 · Change in ownershipOct 28, 2024Insider tradeSEC
144 · Notice of proposed saleOct 25, 2024Other filingsSEC
SC 13G · Big-stake noticeOct 23, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
8-K · Current reportOct 15, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveOct 3, 2024Other filingsSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 1, 2024Insider tradeSEC
CORRESP · Letter to the SECSep 30, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 26, 2024Other filingsSEC
S-3 · Registration statementSep 20, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 19, 2024Other filingsSEC
CORRESP · Letter to the SECSep 13, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 12, 2024Other filingsSEC
S-3 · Registration statementSep 6, 2024Offer documentSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
424B3 · ProspectusAug 7, 2024Offer documentSEC
8-K/A · Current report, amendedAug 7, 2024Current reportSEC
8-K · Current reportAug 7, 2024ResultsSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedJun 10, 2024Big-stake noticeSEC
8-K · Current reportMay 30, 2024Current reportSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 16, 2024Insider tradeSEC

This page holds 200 of 823 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Spyre Therapeutics, Inc.’s releases · as of Nov 3, 2026

Common shares
94,969,184
Fully diluted
94,983,517

Fully diluted

LineSharesAs of
Common shares94,969,184Oct 27, 2026
Options and RSUs14,333Nov 2, 2026

Warrants and options

Lot
Stock options · US$95.51 · expire about Nov 2036
RSUs · expiry not stated

Share count over time

CountShares
Oct 27, 202694,969,184

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Fidelity13.5MUS$1.2BSep 30, 2026
Vanguard8.53MUS$759MSep 30, 2026
BlackRock6.78MUS$604MSep 30, 2026
Paradigm Biocapital Advisors LP4.46MUS$397MSep 30, 2026
Rtw Investments, LP3.69MUS$329MSep 30, 2026
State Street3.53MUS$315MSep 30, 2026
T. Rowe Price3.5MUS$312MSep 30, 2026
Perceptive Advisors LLC3.28MUS$292MSep 30, 2026
Capital Group2.99MUS$267MSep 30, 2026
Janus Henderson2.89MUS$258MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Driehaus Capital Management LLC2.76MUS$246MSep 30, 2026
Geode Capital2.55MUS$236MSep 30, 2026
Venrock Adviser, LLC2.49MUS$221MSep 30, 2026
Franklin Templeton2.04MUS$196MSep 30, 2026
TCG Crossover Management, LLC1.9MUS$169MSep 30, 2026
Tang Capital Management LLC1.89MUS$168MSep 30, 2026
Bank of America1.83MUS$163MSep 30, 2026
Adage Capital Partners Gp, L.L.C.1.77MUS$157MSep 30, 2026
JPMorgan1.73MUS$147MSep 30, 2026
Wellington1.5MUS$134MSep 30, 2026
UBS1.46MUS$130MSep 30, 2026
Affinity Asset Advisors, LLC1.28MUS$114MSep 30, 2026
Goldman Sachs1.2MUS$107MSep 30, 2026
Remedium Capital Partners, LLC1.16MUS$103MSep 30, 2026
Holocene Advisors, LP1.14MUS$102MSep 30, 2026
Schwab1.02MUS$90.5MSep 30, 2026
Polar Capital Holdings Plc985KUS$87.7MSep 30, 2026
Westfield Capital Management Co LP884KUS$78.7MSep 30, 2026
Siren, L.L.C.869KUS$77.3MSep 30, 2026
Braidwell LP714KUS$63.6MSep 30, 2026
Commodore Capital LP700KUS$62.3MSep 30, 2026
Northern Trust697KUS$62.1MSep 30, 2026
Assenagon Asset Management S.A.599KUS$53.3MSep 30, 2026
Emerald Advisers, LLC571KUS$50.8MSep 30, 2026
Victory Capital549KUS$48.8MSep 30, 2026
Marshall Wace, LLP544KUS$48.4MSep 30, 2026
American Century515KUS$45.8MSep 30, 2026
Pictet Asset Management Holding SA479KUS$42.7MSep 30, 2026
Candriam S.C.A.449KUS$40.1MSep 30, 2026
Bellevue Group AG380KUS$33.8MSep 30, 2026
Frontier Capital Management Co LLC372KUS$33.1MSep 30, 2026
Emerald Mutual Fund Advisers Trust366KUS$32.6MSep 30, 2026
Point72 Asset Management, L.P.357KUS$31.8MSep 30, 2026
Voya Investment Management LLC348KUS$31MSep 30, 2026
Integral Health Asset Management, LLC325KUS$8.9MSep 30, 2026
Nuveen321KUS$28.6MSep 30, 2026
Jennison Associates LLC319KUS$28.4MSep 30, 2026
Ameriprise307KUS$27.4MSep 30, 2026
Woodline Partners LP287KUS$25.5MSep 30, 2026
Boxer Capital Management, LLC283KUS$25.2MSep 30, 2026

This page holds 50 of 273 holders. Open Shareholders

Funds

HolderSharesValueAs of
SMALLCAP World Fund Inc2.78MUS$247MJun 30, 2026
Fidelity Growth Company Fund2.58MUS$189MMay 31, 2026
Vanguard Total Stock Market Index Fund2.48MUS$220MJun 30, 2026
iShares Russell 2000 ETF1.91MUS$170MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.33MUS$118MJun 30, 2026
Vanguard Small-Cap Index Fund897KUS$79.6MJun 30, 2026
Vanguard Extended Market Index Fund886KUS$78.7MJun 30, 2026
Fidelity Advisor Biotechnology Fund857KUS$84.3MJul 31, 2026
Fidelity Small Cap Index Fund814KUS$80.1MJul 31, 2026
Fidelity Small Cap Growth Fund778KUS$76.5MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Select Health Care Portfolio760KUS$55.9MMay 31, 2026
Fidelity Growth Company K6 Fund750KUS$55.1MMay 31, 2026
T. Rowe Price Health Sciences Fund, Inc.712KUS$63.2MJun 30, 2026
iShares Russell 2000 Growth ETF688KUS$61MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.674KUS$59.8MJun 30, 2026
Fidelity Series Growth Company Fund671KUS$49.3MMay 31, 2026
Vanguard Small-Cap Value Index Fund568KUS$50.4MJun 30, 2026
iShares Biotechnology ETF548KUS$48.6MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund509KUS$45.2MJun 30, 2026
Vanguard Explorer Fund489KUS$48.1MJul 31, 2026
Select Biotechnology Portfolio403KUS$29.6MMay 31, 2026
Fidelity Extended Market Index Fund384KUS$28.2MMay 31, 2026
Vanguard Russell 2000 Index Fund384KUS$28.2MMay 31, 2026
Fidelity Stock Selector Small Cap Fund383KUS$37.7MJul 31, 2026
Fidelity Small Cap Growth K6 Fund383KUS$37.7MJul 31, 2026
Schwab U.S. Small-Cap ETF360KUS$26.5MMay 31, 2026
Fidelity Advisor Health Care Fund340KUS$33.4MJul 31, 2026
Janus Henderson Global Life Sciences Fund329KUS$29.2MJun 30, 2026
Driehaus Small Cap Growth Fund309KUS$27.4MJun 30, 2026
Fidelity Contrafund296KUS$26.3MJun 30, 2026
Fidelity Series Small Cap Opportunities Fund293KUS$28.8MJul 31, 2026
Putnam Small Cap Growth Fund264KUS$23.4MJun 30, 2026
JPMorgan Small Cap Growth Fund261KUS$23.2MJun 30, 2026
Victory Pioneer Select Mid Cap Growth Fund249KUS$18.3MMay 31, 2026
Franklin Biotechnology Discovery Fund245KUS$24.1MJul 31, 2026
ClearBridge Small Cap Growth Fund210KUS$20.6MJul 31, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund209KUS$20.5MJul 31, 2026
Eventide Healthcare & Life Sciences Fund200KUS$17.8MJun 30, 2026
Franklin Small Cap Growth Fund195KUS$19.2MJul 31, 2026
Schwab Small-Cap Index Fund181KUS$17.8MJul 31, 2026
SmallCap Growth Fund I162KUS$15.9MJul 31, 2026
Emerald Growth Fund153KUS$11.4MApr 30, 2026
Emerald Growth Fund153KUS$15.1MJul 31, 2026
Vanguard Health Care Index Fund147KUS$10.8MMay 31, 2026
Fidelity Total Market Index Fund141KUS$10.4MMay 31, 2026
Fidelity Small Cap Value Fund138KUS$13.5MJul 31, 2026
Master Small Cap Index Series137KUS$12.2MJun 30, 2026
Driehaus Micro Cap Growth Fund134KUS$11.9MJun 30, 2026
VIP Health Care Portfolio128KUS$11.4MJun 30, 2026
Fidelity Series Total Market Index Fund114KUS$8.41MMay 31, 2026

This page holds 50 of 302 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Burrows Scott L
Officer: Chief Financial Officer
Sale600USD 89.07US$53,442Oct 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale1,500USD 90.27US$135KOct 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale2,100USD 91.92US$193KOct 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale3,071USD 92.95US$285KOct 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale229USD 93.57US$21,428Oct 1, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale600USD 89.14US$53,484Oct 1, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale2,683USD 90.10US$242KOct 1, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale2,638USD 91.49US$241KOct 1, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale3,989USD 92.31US$368KOct 1, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale4,990USD 93.37US$466KOct 1, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale100USD 93.91US$9,391Oct 1, 2026
King-Jones Heidy
Officer: See Remarks
Sale400USD 89.24US$35,696Oct 1, 2026
King-Jones Heidy
Officer: See Remarks
Sale16,605USD 90.35US$1.5MOct 1, 2026
King-Jones Heidy
Officer: See Remarks
Sale7,228USD 91.35US$660KOct 1, 2026
King-Jones Heidy
Officer: See Remarks
Sale2,100USD 92.70US$195KOct 1, 2026
King-Jones Heidy
Officer: See Remarks
Sale2,600USD 93.46US$243KOct 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale17,500USD 89.89US$1.57MSep 30, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale18,232USD 89.35US$1.63MSep 2, 2026
King-Jones Heidy
Officer: See Remarks
Sale400USD 90.00US$36,000Sep 2, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale2,500USD 86.36US$216KSep 1, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale8,400USD 87.15US$732KSep 1, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale3,700USD 88.06US$326KSep 1, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale400USD 89.07US$35,628Sep 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale900USD 86.25US$77,625Sep 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale4,384USD 87.11US$382KSep 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale2,016USD 88.03US$177KSep 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale200USD 89.04US$17,808Sep 1, 2026
King-Jones Heidy
Officer: See Remarks
Sale4,845USD 86.40US$419KSep 1, 2026
King-Jones Heidy
Officer: See Remarks
Sale16,548USD 87.20US$1.44MSep 1, 2026
King-Jones Heidy
Officer: See Remarks
Sale6,206USD 88.17US$547KSep 1, 2026
King-Jones Heidy
Officer: See Remarks
Sale400USD 89.38US$35,752Sep 1, 2026
Albers Jeffrey W.
Director
Sale5,000USD 104.47US$522KAug 7, 2026
Albers Jeffrey W.
Director
Sale8,000USD 104.38US$835KAug 7, 2026
Albers Jeffrey W.
Director
Sale10,000USD 104.68US$1.05MAug 7, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale800USD 93.97US$75,176Aug 3, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale7,157USD 95.10US$681KAug 3, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale5,635USD 95.93US$541KAug 3, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale1,392USD 96.82US$135KAug 3, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale16USD 97.46US$1,559Aug 3, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale5,100USD 95.21US$486KAug 3, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale2,300USD 96.30US$221KAug 3, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale100USD 97.10US$9,710Aug 3, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale10,176USD 87.44US$890KJul 1, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale4,234USD 88.12US$373KJul 1, 2026
Turtle Cameron
Director, Officer: Chief Executive Officer
Sale590USD 88.91US$52,457Jul 1, 2026
Sloan Sheldon
Officer: Chief Medical Officer
Sale6,500USD 87.52US$569KJul 1, 2026
Sloan Sheldon
Officer: Chief Medical Officer
Sale1,834USD 88.34US$162KJul 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale5,775USD 87.55US$506KJul 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale1,725USD 88.37US$152KJul 1, 2026
Burrows Scott L
Officer: Chief Financial Officer
Sale5,000USD 87.12US$436KJun 25, 2026

This page holds 50 of 83 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Harwin Peter Evan9.99%10.2MOct 7, 2026Schedule 13D
BlackRock, Inc.6.60%3.96MJun 30, 2025Schedule 13G
Paradigm Biocapital Advisors LP5.10%4.46MSep 24, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Suzanne L. Bruhn
Other companies: Definium Therapeutics, Inc. (Director · Since at least Aug 11, 2022); Vigil Neuroscience Inc (Director · Since at least Jul 27, 2022); Pliant Therapeutics, Inc. (Director · Since at least Jun 2, 2020); Travere Therapeutics, Inc. (Director · Since at least Apr 8, 2020); Avalo Therapeutics, Inc. (Director · Apr 24, 2020 – Nov 10, 2021 · Past); Novelion Therapeutics Inc (Director · Oct 1, 2017 – Aug 9, 2018 · Past); Raptor Pharmaceutical Corp (Director · Sep 25, 2012 – Oct 24, 2016 · Past)
Director · Feb 15, 2017 – Jun 8, 2020 · Past
V Bryan Lawlis
Other companies: Sutro Biopharma, Inc. (Director · Sep 26, 2018 – Sep 26, 2018 · Past); Coherus Oncology, Inc. (Director · Nov 6, 2014 – Jan 11, 2021 · Past); Humanigen Inc (Director · Aug 7, 2013 – Jun 18, 2014 · Past); BioMarin Pharmaceutical Inc. (Director · May 8, 2012 – May 23, 2023 · Past); Geron Corporation (Director · Mar 13, 2012 – May 21, 2025 · Past)
Director · Jul 13, 2018 – Jun 7, 2022 · Past
Ivana Magovčević-Liebisch
Other companies: Quanterix Corporation (Director · Since at least Oct 2, 2024); Acrivon Therapeutics, Inc. (Director · Since at least Feb 8, 2024); Vigil Neuroscience Inc (President and CEO, Director · Since at least Jan 6, 2022); Absci Corporation (Director · Jul 21, 2021 – Jun 8, 2022 · Past)
Director · Jun 8, 2021 – Jun 22, 2023 · Past
Laurie Stelzer
Other companies: MBX Biosciences, Inc. (Director · Since at least Jan 20, 2026); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); PMV Pharmaceuticals, Inc. (Chair, Board of Directors · Since at least Jun 2, 2022); Surface Oncology Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past)
Chair of the Audit Committee · Since at least Nov 22, 2023
Hunter Smith
Other companies: Rhythm Pharmaceuticals, Inc. (Chief Financial Officer and Treasurer · Since at least Oct 4, 2017); Genesee & Wyoming Inc (Director · Jun 30, 2015 – Dec 30, 2019 · Past)
Director · Nov 12, 2021 – Jun 22, 2023 · Past
James Kastenmayer
Other companies: ArriVent BioPharma, Inc. (General Counsel · Since at least Jan 25, 2024); Viela Bio Inc (General Counsel · Jan 6, 2020 – Mar 15, 2021 · Past)
General Counsel · Aug 23, 2022 – Feb 23, 2023 · Past
Madduri Ravin Rao
Other companies: Autolus Therapeutics plc (Director · Since at least Mar 18, 2026); DBV Technologies SA (Director · May 19, 2021 – Jun 10, 2021 · Past)
Chief Medical Officer · Nov 1, 2019 – Feb 14, 2020 · Past
Cameron Turtle
Other companies: Damora Therapeutics, Inc. (Board Director · Since at least Mar 23, 2026)
Chief Executive Officer · Since at least Oct 2, 2026
Jeff Marc Goldberg
Other companies: Akcea Therapeutics Inc (Chief Operating Officer · Jan 2, 2018 – Sep 26, 2019 · Past)
President and CEO, Director · Nov 29, 2022 – Nov 29, 2022 · Past
Scott L Burrows
Other companies: Arcutis Biotherapeutics, Inc. (Chief Financial Officer · Apr 1, 2021 – Mar 6, 2023 · Past)
Chief Financial Officer · Since at least Sep 1, 2023
All 20 people
PersonSeat
David George LoweCEO and President, Director · Apr 6, 2016 – Mar 20, 2017 · Past
Eric McIntyreSVP of Finance and Investor Relations · Since at least Nov 3, 2026
George GeorgiouDirector · Apr 6, 2016 – Aug 13, 2018 · Past
Heidy King-JonesSee Remarks · Since at least Feb 1, 2024
Jeff AlbersChair of the Compensation Committee · Since at least Aug 10, 2026
Leslie SloanChief Operating Officer · Mar 6, 2019 – Aug 23, 2022 · Past
Mark McKennaBoard Member · Since at least Nov 5, 2026
Michael HendersonBoard Member · Since at least Jun 23, 2026
Sandra MilliganChair of the Nominating and Corporate Governance Committee · Since at least Nov 5, 2026
Tomas KiselakMember of the Compensation Committee · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Spyre Therapeutics, Inc.